产品简要
公司名称 :
赛信通(上海)生物试剂有限公司
产品类型 :
抗体
产品名称 :
EGF Receptor (L858R Mutant Specific) (43B2) Rabbit mAb
目录 :
3197
克隆性 :
单克隆
宿主 :
共轭标签 :
nonconjugated
克隆名称 :
43B2
反应物种 :
人类, 小鼠
应用 :
免疫印迹, 免疫组化, 免疫细胞化学, 免疫沉淀, 流式细胞仪
文章摘录数: 31
出版应用/物种/样品/稀释参考文献
  • 免疫组化; 小鼠; 图 4
Amato K, Wang S, Tan L, Hastings A, Song W, Lovly C, et al. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res. 2016;76:305-18 pubmed 出版商
  • 免疫细胞化学; 小鼠
  • 免疫印迹; 小鼠
Bantikassegn A, Song X, Politi K. Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas. Am J Respir Cell Mol Biol. 2015;52:409-17 pubmed 出版商
  • 免疫沉淀; 人类; 1:1000
Tjin Tham Sjin R, Lee K, Walter A, Dubrovskiy A, Sheets M, Martin T, et al. In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing. Mol Cancer Ther. 2014;13:1468-79 pubmed 出版商
  • 免疫印迹; 人类; 1:1000
Pan T, Sun J, Hu J, Hu Y, Zhou J, Chen Z, et al. Cytohesins/ARNO: the function in colorectal cancer cells. PLoS ONE. 2014;9:e90997 pubmed 出版商
Baldi L, Mengoli M, Bisagni A, Banzi M, Boni C, Rossi G. Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. Lung Cancer. 2014;86:291-5 pubmed 出版商
Houang M, Sioson L, Clarkson A, Watson N, Farzin M, Toon C, et al. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology. 2014;46:501-8 pubmed 出版商
Wang X, Wang G, Hao Y, Xu Y, Zhang L. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer. Int J Clin Exp Pathol. 2014;7:4310-6 pubmed
Bondgaard A, Høgdall E, Mellemgaard A, Skov B. High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer. Mod Pathol. 2014;27:1590-8 pubmed 出版商
Secq V, Villeret J, Fina F, Carmassi M, Carcopino X, Garcia S, et al. Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations. Br J Cancer. 2014;110:1045-52 pubmed 出版商
Soma S, Tsuta K, Takano T, Hatanaka Y, Yoshida A, Suzuki K, et al. Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma. Pathol Res Pract. 2014;210:155-60 pubmed 出版商
Kawahara A, Taira T, Abe H, Watari K, Murakami Y, Fukumitsu C, et al. Fixation effect of SurePath preservative fluids using epidermal growth factor receptor mutation-specific antibodies for immunocytochemistry. Cancer Cytopathol. 2014;122:145-52 pubmed 出版商
Ho H, Chang F, Ma H, Liao L, Chuang Y, Chang Chien Y, et al. Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods. Respirology. 2013;18:1261-70 pubmed 出版商
Uramoto H, Yamada S, Tanaka F. Angiogenesis of lung cancer utilizes existing blood vessels rather than developing new vessels using signals from carcinogenesis. Anticancer Res. 2013;33:1913-6 pubmed
Wang Y, Jiang C, Guan J, Yang G, Yue J, Chen H, et al. Molecular alterations of EGFR in small intestinal adenocarcinoma. Int J Colorectal Dis. 2013;28:1329-35 pubmed 出版商
Jiang G, Fan C, Zhang X, Dong Q, Wang L, Liu Y, et al. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer. PLoS ONE. 2013;8:e59183 pubmed 出版商
Fan X, Liu B, Xu H, Yu B, Shi S, Zhang J, et al. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples. Hum Pathol. 2013;44:1499-507 pubmed 出版商
Shiozawa T, Ishii G, Goto K, Nagai K, Mimaki S, Ono S, et al. Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung. Pathol Int. 2013;63:77-84 pubmed 出版商
Kim L, Kim K, Yoon Y, Ryu J, Choi S, Park I, et al. Clinicopathologic and molecular characteristics of lung adenocarcinoma arising in young patients. J Korean Med Sci. 2012;27:1027-36 pubmed 出版商
Angulo B, Conde E, Suarez Gauthier A, Plaza C, Martinez R, Redondo P, et al. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS ONE. 2012;7:e43842 pubmed 出版商
Kawahara A, Taira T, Azuma K, Tominaga M, Hattori S, Kawahara M, et al. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer. 2012;78:39-44 pubmed 出版商
Tabara K, Kanda R, Sonoda K, Kubo T, Murakami Y, Kawahara A, et al. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS ONE. 2012;7:e41017 pubmed 出版商
Shimamura T, Perera S, Foley K, Sang J, Rodig S, Inoue T, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 2012;18:4973-85 pubmed 出版商
Ambrosini Spaltro A, Campanini N, Bortesi B, Azzoni C, Naldi N, Ampollini L, et al. EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a comparison with DNA direct sequencing. Appl Immunohistochem Mol Morphol. 2012;20:356-62 pubmed 出版商
Rimkunas V, Crosby K, Li D, Hu Y, Kelly M, Gu T, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-57 pubmed 出版商
Tsai T, Wu S, Chang Y, Wu C, Tsai M, Wei P, et al. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol. 2012;7:993-1000 pubmed 出版商
Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, Nakayama H, et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 2012;92:371-83 pubmed 出版商
Azuma K, Okamoto I, Kawahara A, Taira T, Nakashima K, Hattori S, et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol. 2012;7:122-7 pubmed 出版商
Simonetti S, Molina M, Queralt C, de Aguirre I, Mayo C, Bertran Alamillo J, et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med. 2010;8:135 pubmed 出版商
Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, Kashihara M, et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res. 2010;16:3163-70 pubmed 出版商
Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn. 2010;12:169-76 pubmed 出版商
Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023-8 pubmed 出版商
产品信息
SKU号 :
3197S
产品名称 :
EGF Receptor (L858R Mutant Specific) (43B2) Rabbit mAb
规格 :
100微升
Price-(USD) :
342美元
物种x :
H
应用 :
流式细胞仪
产品种类 :
RTK
运输温度 :
AMBIENT
储存温度 :
-20°C
产品类型 :
单克隆抗体
分子量 :
175
宿主 :
靶标 :
表皮生长因子受体(Leu858Arg)突变
最初蛋白 :
表皮生长因子受体
别名 :
EGFR,ERBB,ERBB1,Epidermal growth factor receptor,HER1,PIG61,Proto-oncogene c-ErbB-1,Receptor tyrosine-protein kinase erbB-1,avian erythroblastic leukemia viral (v-erb-b) oncogene homolog,cell growth inhibiting protein 40,cell proliferation-inducing protein 61,epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian),mENA
公司信息
赛信通(上海)生物试剂有限公司
上海市浦东南路1101号远东大厦514室,200120
info@cst-c.com.cn
www.cst-c.com.cn
2158356288
公司总部: 美国
赛信通生物试剂有限公司1999年成立于美国麻省,是一家私人拥有的公司,在全世界拥有超过400名员工。我们致力于提供用于帮助确定的细胞功能和抗病机制的创新型的研究工具。公司自成立以来,赛信通已成为全球领先的生产用于扩大细胞信号通路知识的最高质量的激活状态蛋白和总蛋白的抗体。我们的使命是为客户提供世界上最高质量的研究工具,以加快生物研究和个性化药物的进展。